Zunsemetinib
- Generic Name
- Zunsemetinib
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal AdenocarcinomaPancreatic CancerCancer of the Pancreas
- Interventions
- Drug: mFOLFIRINOX
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT06648434
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- Conditions
- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT06374459
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05511519
- Locations
- 🇵🇱
Aclaris Investigational Site, Wrocław, Poland
🇺🇸Aclaris Clinical Operations, Charlotte, North Carolina, United States
ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05216224
- Locations
- 🇺🇸
Aclaris Investigational Site, Sugar Land, Texas, United States
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04524858
- Locations
- 🇺🇸
Aclaris Investigational Site, San Francisco, California, United States
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT04481685
- Locations
- 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04247815
- Locations
- 🇺🇸
Aclaris Investigational Site, Mesquite, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.